PMID- 34555651
OWN - NLM
STAT- MEDLINE
DCOM- 20220128
LR  - 20220128
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 226
DP  - 2021 Oct
TI  - Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A 
      single-institute study of 43 cases.
PG  - 153614
LID - S0344-0338(21)00275-2 [pii]
LID - 10.1016/j.prp.2021.153614 [doi]
AB  - OBJECTIVES: To characterize the clinicopathologic and immunohistochemical 
      features of poorly differentiated neuroendocrine carcinomas (NEC) in the 
      gastrointestinal tract. DESIGN: A total of 43 cases were identified and 
      reassessed based on modern classification. RESULTS: The cohort (27M, 16F; median 
      age: 66 years) included 16 (37%) large cell NEC, 12 (28%) small cell NEC, 5 (12%) 
      NEC not otherwise specified, and 10 (23%) mixed adenoneuroendocrine carcinomas. 
      Tumor predominantly involved the colon (n = 14, 33%), rectum (n = 13, 30%), and 
      esophagus (n = 9, 21%). Immunohistochemically, INSM1 was the most sensitive 
      marker for neuroendocrine differentiation (28/28, 100%), followed by 
      synaptophysin (40/43, 93%), CD56 (22/35, 63%), and chromogranin (18/40, 45%). 
      SATB2, CDX2, CK20, CK7, abnormal p53, and PD-L1 was positive in 21/26 (81%), 
      26/37 (70%), 11/35 (31%), 10/35 (29%), 19/24 (79%), and 12/23 (52%) cases, 
      respectively. Three of 25 (11%) were mismatch repair protein deficient. Of 21 
      resected tumors, 19 (90%) were >/= pT3 and 13 (62%) had nodal metastasis. 
      Twenty-eight (65%) had distant metastasis. The 5-year survival rate was 21%. The 
      prognosis was stage dependent (p < 0.05), but not associated with tumor type, 
      location, or specific immunomarkers. CONCLUSION: Gastrointestinal NECs are 
      aggressive neoplasms. INSM1, synaptophysin, and SATB2 are sensitive markers, 
      although not site or tumor type specific.
CI  - Copyright (c) 2021. Published by Elsevier GmbH.
FAU - Chen, Irene
AU  - Chen I
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, USA.
FAU - Zhang, Dongwei
AU  - Zhang D
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, USA.
FAU - Velez, Moises
AU  - Velez M
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, USA.
FAU - Kovar, Sierra
AU  - Kovar S
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, USA.
FAU - Liao, Xiaoyan
AU  - Liao X
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, NY, USA. Electronic address: Xiaoyan_liao@urmc.rochester.edu.
LA  - eng
PT  - Journal Article
DEP - 20210911
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Neuroendocrine/*pathology
MH  - Female
MH  - Gastrointestinal Neoplasms/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
OTO - NOTNLM
OT  - INSM1
OT  - Neuroendocrine carcinoma
OT  - PD-L1
OT  - Prognosis
OT  - SATB2
EDAT- 2021/09/24 06:00
MHDA- 2022/01/29 06:00
CRDT- 2021/09/23 20:21
PHST- 2021/08/08 00:00 [received]
PHST- 2021/09/05 00:00 [revised]
PHST- 2021/09/08 00:00 [accepted]
PHST- 2021/09/24 06:00 [pubmed]
PHST- 2022/01/29 06:00 [medline]
PHST- 2021/09/23 20:21 [entrez]
AID - S0344-0338(21)00275-2 [pii]
AID - 10.1016/j.prp.2021.153614 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2021 Oct;226:153614. doi: 10.1016/j.prp.2021.153614. Epub 2021 
      Sep 11.